Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia.

ABSTRACT: High-throughput omics have proven invaluable in studying human disease, and yet day-to-day clinical practice still relies on physiological, non-omic markers. The metabolic syndrome, for example, is diagnosed and monitored by blood and urine indices such as blood cholesterol levels. Nevertheless, the association between the molecular and the physiological manifestations of the disease, especially in response to treatment, has not been investigated in a systematic manner. To this end, we studied a mouse model of diet-induced dyslipidemia and atherosclerosis that was subject to various drug treatments relevant to the disease in question. Both physiological data and gene expression data (from the liver and white adipose) were analyzed and compared. We find that treatments that restore gene exp

SUBMITTER: Wagner A 

PROVIDER: S-EPMC4380926 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature